Compare PEBO & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | MPLT |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2005 | 2025 |
| Metric | PEBO | MPLT |
|---|---|---|
| Price | $39.48 | $11.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $37.33 | $32.67 |
| AVG Volume (30 Days) | 194.6K | ★ 522.1K |
| Earning Date | 04-21-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | N/A | ★ 82.39 |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $197,000.00 | N/A |
| Revenue This Year | $17.29 | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.49 | $9.10 |
| 52 Week High | $42.29 | $40.43 |
| Indicator | PEBO | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 52.00 | 35.27 |
| Support Level | $38.86 | $10.67 |
| Resistance Level | $41.59 | $14.22 |
| Average True Range (ATR) | 0.51 | 0.90 |
| MACD | 0.04 | 0.38 |
| Stochastic Oscillator | 86.55 | 1.25 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.